Peng Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Peng Zhang has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Zhang Liu
Department of Cardio-Thoracic Surgery, Shanghai Tenth People’s Hospital, School of Medicine, Tongji University, Shanghai 200072, China
3 shared publications - Zhen Yu
Department of Gastrointestinal Surgery, Shanghai Tenth People's Hospital, School of Medicine Tongji University Shanghai China
3 shared publications - Zile Shen
Department of Gastrointestinal Surgery, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, China
3 shared publications - Xia-Lin Yan
Department of Colorectal Anal Surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, China
2 shared publications Ding-Ye Yu
Department of General Surgery, Huadong Hospital, Fudan University, Shanghai 200040, China
1 shared publicationGuowei Huang
Department of Gastrointestinal Surgery, Shanghai Tenth People's Hospital, School of Medicine Tongji University Shanghai China
1 shared publication
Latest Publications
- Open Access
- 1 January 2026
- Published by Wiley in Journal of Cachexia, Sarcopenia and Muscle
- Vol. 17 (2) , e70282
Dual Roles of CCN5/WISP2 in Cytosol and Secretome for Maintaining Muscle Homeostasis and Preventing Sarcopenia
Background: Sarcopenia is a progressive and systemic skeletal muscle disorder characterized by the decline of muscle mass and function. Despite its early‐stage, ‘possible sarcopenia’ has been emphasized for prompt intervention; there are currently no specific biomarkers for the diagnosis and treatment. Methods: RNA sequencing of human skeletal muscle across sarcopenia stages identified CCN5. Adeno‐associated virus (AAV) is intramuscularly injected into young C57BL/6J mice to knockdown CCN5 in skeletal muscle. Phenotypic alterations are assessed through behavioural testing, body composition analysis, oil red O staining and transmission electron microscopy. Mechanisms were investigated in C2C12 myotubes using lentiviral infection, Western blotting, immunofluorescence, cellular electron microscopy and seahorse assays. Finally, aged C57BL/6J mice received intramuscular AAV injections to overexpress CCN5 in skeletal muscle, evaluating its therapeutic efficacy against sarcopenia. Results: Clinical samples included 56 participants (48.2% female; mean age: 63.21 ± 8.76 years). By comparing gene expression in human skeletal muscle across three stages of sarcopenia, we identified CCN5 as a gene exhibiting decreased protein expression in possible sarcopenia stage (approximately 33% reduction, p = 0.0245), with this decline persisting into sarcopenia stage ( p = 0.0093). In young mice, CCN5 knockdown induced a sarcopenia‐like phenotype, encompassing skeletal muscle dysfunction and myosteatosis (fat mass: p < 0.01; intramyocellular triglyceride: 66.02 ± 3.798 vs. 104.5 ± 8.542 μg/mg tissue, p < 0.01). CCN5 deficiency also impaired mitochondrial content and function, particularly by reducing lipid droplet‐mitochondrial (LD‐Mt) interaction (approximately 47% reduction, p < 0.05). In C2C12 cells, CCN5 knockdown disrupted lipid metabolism (particularly reduced lipid oxidation, CPT1A: approximately 56% reduction, p < 0.001), promoted lipid accumulation and compromised mitochondrial content and function. Mechanistically, secreted CCN5 enhanced LD‐Mt interaction and stimulated mitochondrial biogenesis by activating nuclear β‐catenin translocation to enhance FOXO3A‐dependent transcription, while intracellular CCN5 mitigated myosteatosis by inhibiting PPARγ signalling. In aged mice, CCN5 overexpression improved skeletal muscle function, reduced myosteatosis (fat mass: p < 0.001; intramyocellular triglyceride: 175.0 ± 11.18 vs. 92.18 ± 10.53 μg/mg tissue, p < 0.001) and restored mitochondrial function. Conclusions: CCN5 mitigates myosteatosis and counteracts sarcopenia by promoting mitochondrial biogenesis and enhancing LD‐Mt interactions through dual pathways, positioning it as a promising therapeutic target for muscle aging and sarcopenia.
- 1 January 2026
- Published by Wiley in Journal of Cachexia, Sarcopenia and Muscle
- Vol. 17 (2) , e70282
Open AccessDual Roles of CCN5/WISP2 in Cytosol and Secretome for Maintaining Muscle Homeostasis and Preventing Sarcopenia
Background: Sarcopenia is a progressive and systemic skeletal muscle disorder characterized by the decline of muscle mass and function. Despite its early‐stage, ‘possible sarcopenia’ has been emphasized for prompt intervention; there are currently no specific biomarkers for the diagnosis and treatment. Methods: RNA sequencing of human skeletal muscle across sarcopenia stages identified CCN5. Adeno‐associated virus (AAV) is intramuscularly injected into young C57BL/6J mice to knockdown CCN5 in skeletal muscle. Phenotypic alterations are assessed through behavioural testing, body composition analysis, oil red O staining and transmission electron microscopy. Mechanisms were investigated in C2C12 myotubes using lentiviral infection, Western blotting, immunofluorescence, cellular electron microscopy and seahorse assays. Finally, aged C57BL/6J mice received intramuscular AAV injections to overexpress CCN5 in skeletal muscle, evaluating its therapeutic efficacy against sarcopenia. Results: Clinical samples included 56 participants (48.2% female; mean age: 63.21 ± 8.76 years). By comparing gene expression in human skeletal muscle across three stages of sarcopenia, we identified CCN5 as a gene exhibiting decreased protein expression in possible sarcopenia stage (approximately 33% reduction, p = 0.0245), with this decline persisting into sarcopenia stage ( p = 0.0093). In young mice, CCN5 knockdown induced a sarcopenia‐like phenotype, encompassing skeletal muscle dysfunction and myosteatosis (fat mass: p < 0.01; intramyocellular triglyceride: 66.02 ± 3.798 vs. 104.5 ± 8.542 μg/mg tissue, p < 0.01). CCN5 deficiency also impaired mitochondrial content and function, particularly by reducing lipid droplet‐mitochondrial (LD‐Mt) interaction (approximately 47% reduction, p < 0.05). In C2C12 cells, CCN5 knockdown disrupted lipid metabolism (particularly reduced lipid oxidation, CPT1A: approximately 56% reduction, p < 0.001), promoted lipid accumulation and compromised mitochondrial content and function. Mechanistically, secreted CCN5 enhanced LD‐Mt interaction and stimulated mitochondrial biogenesis by activating nuclear β‐catenin translocation to enhance FOXO3A‐dependent transcription, while intracellular CCN5 mitigated myosteatosis by inhibiting PPARγ signalling. In aged mice, CCN5 overexpression improved skeletal muscle function, reduced myosteatosis (fat mass: p < 0.001; intramyocellular triglyceride: 175.0 ± 11.18 vs. 92.18 ± 10.53 μg/mg tissue, p < 0.001) and restored mitochondrial function. Conclusions: CCN5 mitigates myosteatosis and counteracts sarcopenia by promoting mitochondrial biogenesis and enhancing LD‐Mt interactions through dual pathways, positioning it as a promising therapeutic target for muscle aging and sarcopenia.
- Open Access
- 20 June 2023
- Published by Elsevier in Experimental Gerontology
- Vol. 179, 112244
A novel insight into the key gene signature associated with the immune landscape in the progression of sarcopenia
- 20 June 2023
- Published by Elsevier in Experimental Gerontology
- Vol. 179, 112244
Open AccessA novel insight into the key gene signature associated with the immune landscape in the progression of sarcopenia
- Open Access
Development and Validation of Global Leadership Initiative on Malnutrition for Prognostic Prediction in Patients Who Underwent Cardiac Surgery
The Global Leadership Initiative on Malnutrition (GLIM) has achieved a consensus for the diagnosis of malnutrition in recent years. This study aims to determine the prognostic effect of the GLIM after cardiac surgery. A total of 603 patients in the training cohort and 258 patients in the validation cohort were enrolled in this study. Perioperative characteristics and follow-up data were collected. A nomogram based on independent prognostic predictors was developed for survival prediction. In total, 114 (18.9%) and 48 (18.6%) patients were defined as being malnourished according to the GLIM criteria in the two cohorts, respectively. Multivariate regression analysis showed that GLIM-defined malnutrition was an independent risk factor of total complication (OR 1.661, 95% CI: 1.063–2.594) and overall survival (HR 2.339, 95% CI: 1.504–3.637). The c-index was 0.72 (95% CI: 0.66–0.79) and AUC were 0.800, 0.798, and 0.780 for 1-, 2-, and 3-year survival prediction, respectively. The calibration curves of the nomogram fit well. In conclusion, GLIM criteria can efficiently identify malnutrition and has a prognostic effect on clinical outcomes after cardiac surgery. GLIM-based nomogram has favorable performance in survival prediction.
Open AccessDevelopment and Validation of Global Leadership Initiative on Malnutrition for Prognostic Prediction in Patients Who Underwent Cardiac Surgery
The Global Leadership Initiative on Malnutrition (GLIM) has achieved a consensus for the diagnosis of malnutrition in recent years. This study aims to determine the prognostic effect of the GLIM after cardiac surgery. A total of 603 patients in the training cohort and 258 patients in the validation cohort were enrolled in this study. Perioperative characteristics and follow-up data were collected. A nomogram based on independent prognostic predictors was developed for survival prediction. In total, 114 (18.9%) and 48 (18.6%) patients were defined as being malnourished according to the GLIM criteria in the two cohorts, respectively. Multivariate regression analysis showed that GLIM-defined malnutrition was an independent risk factor of total complication (OR 1.661, 95% CI: 1.063–2.594) and overall survival (HR 2.339, 95% CI: 1.504–3.637). The c-index was 0.72 (95% CI: 0.66–0.79) and AUC were 0.800, 0.798, and 0.780 for 1-, 2-, and 3-year survival prediction, respectively. The calibration curves of the nomogram fit well. In conclusion, GLIM criteria can efficiently identify malnutrition and has a prognostic effect on clinical outcomes after cardiac surgery. GLIM-based nomogram has favorable performance in survival prediction.